# Tricaprilin Liquid Formulation PK Study

> **NCT05028114** · PHASE1 · TERMINATED · sponsor: **Cerecin** · enrollment: 71 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** AC-1202
- **DRUG:** AC-OLE-01
- **DRUG:** AC-OLE-02
- **DRUG:** AC-OLE-03
- **DRUG:** AC-OLE-04
- **DRUG:** AC-OLE-05
- **DRUG:** AC-OLE-06
- **DRUG:** AC-OLE-07
- **DRUG:** AC-OLE-08
- **DRUG:** AC-OLE-09
- **DRUG:** AC-OLE-010
- **DRUG:** AC-OLE-P

## Key facts

- **NCT ID:** NCT05028114
- **Lead sponsor:** Cerecin
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-31
- **Primary completion:** 2022-03-18
- **Final completion:** 2022-07-19
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** Part 1 was completed, Part 2 and Part 3 of the study were not conducted under this study protocol due to subject recruitment difficulty.
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05028114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05028114, "Tricaprilin Liquid Formulation PK Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05028114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*